The prognostic significance of postoperative neutrophil-tolymphocyte ratio after radical prostatectomy for localized prostate cancer

Won Sik Jang, Kang Su Cho, Myung Soo Kim, Cheol Yong Yoon, Dong Hyuk Kang, Yong Jin Kang, Won Sik Jeong, Won Sik Ham, Young Deuk Choi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The pretreatment neutrophil-to-lymphocyte ratio has prognostic value after radical prostatectomy for treating localized prostate cancer. However, the use of postoperative neutrophil-to-lymphocyte ratio has not been evaluated in this population. We investigated the prognostic significance of early postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for prostate cancer. Methods: We retrospectively reviewed clinical data from 2,302 patients with localized prostate cancer who underwent radical prostatectomy at our institution between years 2000 and 2010. Only patients with pre- and postoperative complete blood counts with differential results were included. Patients who received neoadjuvant or postoperative adjuvant treatment and those without adequate medical records were excluded. Kaplan-Meier analyses were performed to analyze biochemical recurrence-free survival and overall survival rates. Univariate and multivariate Cox regression models were used for each endpoint. Results: Kaplan-Meier curves showed that high postoperative neutrophil-tolymphocyte ratio (>3.5) was significantly associated with decreased biochemical recurrence-free survival (p = 0.009) and overall survival (p = 0.010). In the univariate and multivariate Cox regression analyses, high postoperative neutrophilto- lymphocyte ratio was a significant predictor of biochemical recurrence (hazard ratio 1.270, p = 0.008) and overall survival (hazard ratio 1.437, p = 0.033). Conclusions: Our results demonstrate that postoperative neutrophil-tolymphocyte ratio is an independent factor for biochemical recurrence and overall survival in patients who underwent radical prostatectomy for prostate cancer. These findings suggest that neutrophil-to-lymphocyte ratio can be a potentially valuable tool for stratifying high-risk patients and facilitating choices of postoperative therapy in patients with prostate cancer.

Original languageEnglish
Pages (from-to)11778-11787
Number of pages10
JournalOncotarget
Volume8
Issue number7
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Prostatectomy
Prostatic Neoplasms
Neutrophils
Lymphocytes
Survival
Recurrence
Blood Cell Count
Kaplan-Meier Estimate
Proportional Hazards Models
Medical Records
Survival Rate
Regression Analysis
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Jang, Won Sik ; Cho, Kang Su ; Kim, Myung Soo ; Yoon, Cheol Yong ; Kang, Dong Hyuk ; Kang, Yong Jin ; Jeong, Won Sik ; Ham, Won Sik ; Choi, Young Deuk. / The prognostic significance of postoperative neutrophil-tolymphocyte ratio after radical prostatectomy for localized prostate cancer. In: Oncotarget. 2017 ; Vol. 8, No. 7. pp. 11778-11787.
@article{be1a750b907740c699038bc21b572cf2,
title = "The prognostic significance of postoperative neutrophil-tolymphocyte ratio after radical prostatectomy for localized prostate cancer",
abstract = "Background: The pretreatment neutrophil-to-lymphocyte ratio has prognostic value after radical prostatectomy for treating localized prostate cancer. However, the use of postoperative neutrophil-to-lymphocyte ratio has not been evaluated in this population. We investigated the prognostic significance of early postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for prostate cancer. Methods: We retrospectively reviewed clinical data from 2,302 patients with localized prostate cancer who underwent radical prostatectomy at our institution between years 2000 and 2010. Only patients with pre- and postoperative complete blood counts with differential results were included. Patients who received neoadjuvant or postoperative adjuvant treatment and those without adequate medical records were excluded. Kaplan-Meier analyses were performed to analyze biochemical recurrence-free survival and overall survival rates. Univariate and multivariate Cox regression models were used for each endpoint. Results: Kaplan-Meier curves showed that high postoperative neutrophil-tolymphocyte ratio (>3.5) was significantly associated with decreased biochemical recurrence-free survival (p = 0.009) and overall survival (p = 0.010). In the univariate and multivariate Cox regression analyses, high postoperative neutrophilto- lymphocyte ratio was a significant predictor of biochemical recurrence (hazard ratio 1.270, p = 0.008) and overall survival (hazard ratio 1.437, p = 0.033). Conclusions: Our results demonstrate that postoperative neutrophil-tolymphocyte ratio is an independent factor for biochemical recurrence and overall survival in patients who underwent radical prostatectomy for prostate cancer. These findings suggest that neutrophil-to-lymphocyte ratio can be a potentially valuable tool for stratifying high-risk patients and facilitating choices of postoperative therapy in patients with prostate cancer.",
author = "Jang, {Won Sik} and Cho, {Kang Su} and Kim, {Myung Soo} and Yoon, {Cheol Yong} and Kang, {Dong Hyuk} and Kang, {Yong Jin} and Jeong, {Won Sik} and Ham, {Won Sik} and Choi, {Young Deuk}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14349",
language = "English",
volume = "8",
pages = "11778--11787",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "7",

}

The prognostic significance of postoperative neutrophil-tolymphocyte ratio after radical prostatectomy for localized prostate cancer. / Jang, Won Sik; Cho, Kang Su; Kim, Myung Soo; Yoon, Cheol Yong; Kang, Dong Hyuk; Kang, Yong Jin; Jeong, Won Sik; Ham, Won Sik; Choi, Young Deuk.

In: Oncotarget, Vol. 8, No. 7, 01.01.2017, p. 11778-11787.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The prognostic significance of postoperative neutrophil-tolymphocyte ratio after radical prostatectomy for localized prostate cancer

AU - Jang, Won Sik

AU - Cho, Kang Su

AU - Kim, Myung Soo

AU - Yoon, Cheol Yong

AU - Kang, Dong Hyuk

AU - Kang, Yong Jin

AU - Jeong, Won Sik

AU - Ham, Won Sik

AU - Choi, Young Deuk

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: The pretreatment neutrophil-to-lymphocyte ratio has prognostic value after radical prostatectomy for treating localized prostate cancer. However, the use of postoperative neutrophil-to-lymphocyte ratio has not been evaluated in this population. We investigated the prognostic significance of early postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for prostate cancer. Methods: We retrospectively reviewed clinical data from 2,302 patients with localized prostate cancer who underwent radical prostatectomy at our institution between years 2000 and 2010. Only patients with pre- and postoperative complete blood counts with differential results were included. Patients who received neoadjuvant or postoperative adjuvant treatment and those without adequate medical records were excluded. Kaplan-Meier analyses were performed to analyze biochemical recurrence-free survival and overall survival rates. Univariate and multivariate Cox regression models were used for each endpoint. Results: Kaplan-Meier curves showed that high postoperative neutrophil-tolymphocyte ratio (>3.5) was significantly associated with decreased biochemical recurrence-free survival (p = 0.009) and overall survival (p = 0.010). In the univariate and multivariate Cox regression analyses, high postoperative neutrophilto- lymphocyte ratio was a significant predictor of biochemical recurrence (hazard ratio 1.270, p = 0.008) and overall survival (hazard ratio 1.437, p = 0.033). Conclusions: Our results demonstrate that postoperative neutrophil-tolymphocyte ratio is an independent factor for biochemical recurrence and overall survival in patients who underwent radical prostatectomy for prostate cancer. These findings suggest that neutrophil-to-lymphocyte ratio can be a potentially valuable tool for stratifying high-risk patients and facilitating choices of postoperative therapy in patients with prostate cancer.

AB - Background: The pretreatment neutrophil-to-lymphocyte ratio has prognostic value after radical prostatectomy for treating localized prostate cancer. However, the use of postoperative neutrophil-to-lymphocyte ratio has not been evaluated in this population. We investigated the prognostic significance of early postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for prostate cancer. Methods: We retrospectively reviewed clinical data from 2,302 patients with localized prostate cancer who underwent radical prostatectomy at our institution between years 2000 and 2010. Only patients with pre- and postoperative complete blood counts with differential results were included. Patients who received neoadjuvant or postoperative adjuvant treatment and those without adequate medical records were excluded. Kaplan-Meier analyses were performed to analyze biochemical recurrence-free survival and overall survival rates. Univariate and multivariate Cox regression models were used for each endpoint. Results: Kaplan-Meier curves showed that high postoperative neutrophil-tolymphocyte ratio (>3.5) was significantly associated with decreased biochemical recurrence-free survival (p = 0.009) and overall survival (p = 0.010). In the univariate and multivariate Cox regression analyses, high postoperative neutrophilto- lymphocyte ratio was a significant predictor of biochemical recurrence (hazard ratio 1.270, p = 0.008) and overall survival (hazard ratio 1.437, p = 0.033). Conclusions: Our results demonstrate that postoperative neutrophil-tolymphocyte ratio is an independent factor for biochemical recurrence and overall survival in patients who underwent radical prostatectomy for prostate cancer. These findings suggest that neutrophil-to-lymphocyte ratio can be a potentially valuable tool for stratifying high-risk patients and facilitating choices of postoperative therapy in patients with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85012884107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012884107&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14349

DO - 10.18632/oncotarget.14349

M3 - Article

C2 - 28052031

AN - SCOPUS:85012884107

VL - 8

SP - 11778

EP - 11787

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -